Inhibikase Therapeutics, INC. (IKT) — 10-Q Filings

10-Q Filings (6)

• Inhibikase Losses Mount Amid Soaring R&D for PAH Drug — Nov 14, 2025 Risk: high
  Inhibikase Therapeutics, Inc. (IKT) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $35,524,538, compared to
• Inhibikase Losses Soar 145% on R&D Boost, Cash Position Strong — Aug 14, 2025 Risk: high
  Inhibikase Therapeutics, Inc. (IKT) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $23,594,258, a substantial rise
• Inhibikase Therapeutics Files Q1 2025 10-Q — May 14, 2025 Risk: medium
  Inhibikase Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, incl
• Inhibikase Therapeutics Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and results of operations
• Inhibikase Therapeutics Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its busines
• Inhibikase Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: medium
  Inhibikase Therapeutics, Inc. (IKT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Inhibikase Therapeutics, Inc. filed a 10-Q report for the quar

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX